Shots:

• Morphic will receive a $20M as license fee and is eligible to receive milestones and royalties on sales of any commercialized therapy while AbbVie has exercised a license option under the companies’ R&D collaboration agreement to develop Morphic’s αvβ6 integrin inhibitors for fibrotic diseases including IPF and additional indications
• The license covers αvβ6 integrin inhibitors including MORF-720 and MORF-627- supported by an extensive preclinical data demonstrating potential as treatments for IPF as well as other fibrotic diseases
• Under the original deal- Morphic would handle R&D work on its pipeline through IND-enabling studies- after which AbbVie has an option to take each compound for global development and commercialization

­ Ref: AbbVie | Image: abbvie